Irhythm Technologies, Inc. (IRTC)

$116.43

+0.09

(+0.08%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Irhythm Technologies, Inc.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 111.43M → 132.51M (in $), with an average increase of 5.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -18.48M → -38.69M (in $), with an average decrease of 44.7% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 35.0% return, outperforming this stock by 48.7%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 61.5% return, outperforming this stock by 15.6%

Performance

  • $115.23
    $118.43
    $116.43
    downward going graph

    1.03%

    Downside

    Day's Volatility :2.71%

    Upside

    1.69%

    downward going graph
  • $70.24
    $138.64
    $116.43
    downward going graph

    39.67%

    Downside

    52 Weeks Volatility :49.34%

    Upside

    16.02%

    downward going graph

Returns

PeriodIrhythm Technologies, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-1.51%
2.0%
0.0%
6 Months
54.33%
11.7%
0.0%
1 Year
-13.66%
5.8%
1.3%
3 Years
40.91%
14.2%
-22.1%

Highlights

Market Capitalization
3.5B
Book Value
$6.79
Earnings Per Share (EPS)
-4.04
PEG Ratio
0.0
Wall Street Target Price
139.11
Profit Margin
-25.05%
Operating Margin TTM
-19.87%
Return On Assets TTM
-13.93%
Return On Equity TTM
-54.86%
Revenue TTM
492.7M
Revenue Per Share TTM
16.14
Quarterly Revenue Growth YOY
17.7%
Gross Profit TTM
281.6M
EBITDA
-94.1M
Diluted Eps TTM
-4.04
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.91
EPS Estimate Next Year
-1.71
EPS Estimate Current Quarter
-0.6
EPS Estimate Next Quarter
-0.72

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Irhythm Technologies, Inc.(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 19.48%

Current $116.43
Target $139.11

Company Financials

FY18Y/Y Change
Revenue
147.3M
↑ 49.52%
Net Income
-48.3M
↑ 64.11%
Net Profit Margin
-32.78%
↓ 2.91%
FY19Y/Y Change
Revenue
214.6M
↑ 45.66%
Net Income
-54.6M
↑ 13.02%
Net Profit Margin
-25.43%
↑ 7.35%
FY20Y/Y Change
Revenue
265.2M
↑ 23.59%
Net Income
-43.8M
↓ 19.68%
Net Profit Margin
-16.53%
↑ 8.9%
FY21Y/Y Change
Revenue
322.8M
↑ 21.74%
Net Income
-101.4M
↑ 131.26%
Net Profit Margin
-31.4%
↓ 14.87%
FY22Y/Y Change
Revenue
410.9M
↑ 27.29%
Net Income
-116.2M
↑ 14.6%
Net Profit Margin
-28.27%
↑ 3.13%
FY23Y/Y Change
Revenue
492.7M
↑ 19.9%
Net Income
-123.4M
↑ 6.24%
Net Profit Margin
-25.05%
↑ 3.22%
Q3 FY22Q/Q Change
Revenue
103.9M
↑ 1.79%
Net Income
-21.5M
↓ 10.24%
Net Profit Margin
-20.65%
↑ 2.77%
Q4 FY22Q/Q Change
Revenue
112.6M
↑ 8.42%
Net Income
-20.2M
↓ 5.84%
Net Profit Margin
-17.94%
↑ 2.71%
Q1 FY23Q/Q Change
Revenue
111.4M
↓ 1.05%
Net Income
-39.1M
↑ 93.63%
Net Profit Margin
-35.1%
↓ 17.16%
Q2 FY23Q/Q Change
Revenue
124.1M
↑ 11.39%
Net Income
-18.5M
↓ 52.74%
Net Profit Margin
-14.89%
↑ 20.21%
Q3 FY23Q/Q Change
Revenue
124.6M
↑ 0.38%
Net Income
-27.1M
↑ 46.72%
Net Profit Margin
-21.76%
↓ 6.87%
Q4 FY23Q/Q Change
Revenue
132.5M
↑ 6.35%
Net Income
-38.7M
↑ 42.72%
Net Profit Margin
-29.2%
↓ 7.44%
FY18Y/Y Change
Total Assets
119.7M
↓ 10.08%
Total Liabilities
65.3M
↑ 21.87%
FY19Y/Y Change
Total Assets
306.2M
↑ 155.79%
Total Liabilities
170.8M
↑ 161.61%
FY20Y/Y Change
Total Assets
511.7M
↑ 67.12%
Total Liabilities
170.1M
↓ 0.4%
FY21Y/Y Change
Total Assets
463.0M
↓ 9.53%
Total Liabilities
183.5M
↑ 7.83%
FY22Y/Y Change
Total Assets
448.2M
↓ 3.18%
Total Liabilities
208.4M
↑ 13.6%
FY23Y/Y Change
Total Assets
433.1M
↓ 3.36%
Total Liabilities
223.0M
↑ 7.02%
Q3 FY22Q/Q Change
Total Assets
440.4M
↑ 1.08%
Total Liabilities
201.2M
↑ 5.3%
Q4 FY22Q/Q Change
Total Assets
448.2M
↑ 1.78%
Total Liabilities
208.4M
↑ 3.6%
Q1 FY23Q/Q Change
Total Assets
421.7M
↓ 5.92%
Total Liabilities
199.9M
↓ 4.1%
Q2 FY23Q/Q Change
Total Assets
429.5M
↑ 1.85%
Total Liabilities
205.6M
↑ 2.87%
Q3 FY23Q/Q Change
Total Assets
439.8M
↑ 2.39%
Total Liabilities
220.0M
↑ 6.99%
Q4 FY23Q/Q Change
Total Assets
433.1M
↓ 1.51%
Total Liabilities
223.0M
↑ 1.4%
FY18Y/Y Change
Operating Cash Flow
-29.1M
↑ 94.94%
Investing Cash Flow
34.1M
↓ 198.37%
Financing Cash Flow
6.3M
↓ 3.51%
FY19Y/Y Change
Operating Cash Flow
-21.9M
↓ 24.79%
Investing Cash Flow
-89.3M
↓ 361.67%
Financing Cash Flow
111.6M
↑ 1670.2%
FY20Y/Y Change
Operating Cash Flow
-13.8M
↓ 37.07%
Investing Cash Flow
-132.4M
↑ 48.3%
Financing Cash Flow
214.3M
↑ 92.08%
FY21Y/Y Change
Operating Cash Flow
-37.8M
↑ 174.39%
Investing Cash Flow
105.3M
↓ 179.51%
Financing Cash Flow
-28.6M
↓ 113.33%
FY22Y/Y Change
Operating Cash Flow
-23.0M
↓ 39.05%
Investing Cash Flow
-52.4M
↓ 149.81%
Financing Cash Flow
26.7M
↓ 193.49%
Q3 FY22Q/Q Change
Operating Cash Flow
3.7M
↓ 1086.29%
Investing Cash Flow
-35.4M
↑ 8104.64%
Financing Cash Flow
1.7M
↓ 77.14%
Q4 FY22Q/Q Change
Operating Cash Flow
12.6M
↑ 242.76%
Investing Cash Flow
-8.1M
↓ 77.05%
Financing Cash Flow
3.1M
↑ 89.41%
Q1 FY23Q/Q Change
Operating Cash Flow
-30.8M
↓ 344.54%
Investing Cash Flow
3.8M
↓ 147.08%
Financing Cash Flow
905.0K
↓ 71.25%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.6M
↓ 85.13%
Investing Cash Flow
9.0M
↑ 135.84%
Financing Cash Flow
4.4M
↑ 384.09%
Q3 FY23Q/Q Change
Operating Cash Flow
1.2M
↓ 126.16%
Investing Cash Flow
-15.4M
↓ 271.36%
Financing Cash Flow
66.0K
↓ 98.49%

Technicals Summary

Sell

Neutral

Buy

Irhythm Technologies, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Irhythm Technologies, Inc.
Irhythm Technologies, Inc.
3.36%
54.33%
-13.66%
40.91%
57.08%
Stryker Corporation
Stryker Corporation
-4.59%
29.28%
11.83%
26.25%
78.93%
Boston Scientific Corp.
Boston Scientific Corp.
2.53%
38.01%
34.98%
63.21%
86.81%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-5.81%
24.49%
-1.17%
-8.62%
48.12%
Abbott Laboratories
Abbott Laboratories
-2.2%
13.48%
-2.16%
-12.23%
37.74%
Medtronic Plc
Medtronic Plc
-3.44%
13.85%
-10.38%
-37.53%
-7.46%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Irhythm Technologies, Inc.
Irhythm Technologies, Inc.
NA
NA
0.0
-2.91
-0.55
-0.14
NA
6.79
Stryker Corporation
Stryker Corporation
39.67
39.67
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.57
63.57
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
38.15
38.15
5.19
2.75
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.36
33.36
5.99
4.61
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.58
25.58
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Irhythm Technologies, Inc.
Irhythm Technologies, Inc.
Buy
$3.5B
57.08%
NA
-25.05%
Stryker Corporation
Stryker Corporation
Buy
$124.7B
78.93%
39.67
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.0B
86.81%
63.57
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.8B
48.12%
38.15
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$185.8B
37.74%
33.36
13.96%
Medtronic Plc
Medtronic Plc
Buy
$107.0B
-7.46%
25.58
13.0%

Institutional Holdings

  • Vanguard Group Inc

    9.66%

  • Capital Research Global Investors

    8.05%

  • BlackRock Inc

    8.05%

  • Sands Capital Management, LLC

    7.22%

  • Artisan Partners Limited Partnership

    6.69%

  • AllianceBernstein L.P.

    4.16%

Corporate Announcements

  • Irhythm Technologies, Inc. Earnings

    Irhythm Technologies, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

Organization
Irhythm Technologies, Inc.
Employees
2000
CEO
Mr. Quentin S. Blackford
Industry
Health Technology

Discover More

FAQs